A randomized control trial of the efficacy and safety of sublingual versus vaginal misoprostol for induction of labour in Ahmadu Bello University Teaching Hospital-Zaria.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511783268861

Enrollment

120

Registered

2025-11-18

Start date

2024-01-08

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

Sublingual misoprostol

Vaginal misoprostol

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: All consenting women scheduled for induction of labour at 37weeks and beyond, having singleton viable gestation, vertex presentation and of parity of 4 and below with a Bishop Score of less than 7

Exclusion criteria

Exclusion criteria: Previous uterine scar, Prelabour rupture of membrane, Antepartum haemorrhage, Women already in labour, Abnormal biophysical profile of =6, Estimated fetal weight greater than 4,000g, Women with renal disease, Women with hepatic dysfunction, and Women with known hypersensitivity to prostaglandins.

Design outcomes

Primary

Measure	Time frame
?Percentage of parturients that deliver vaginally after maximum dose of misoprostol (4 doses in 24 hours) in both groups of the study.	—

Secondary

Measure	Time frame
? The induction-delivery interval in both groups of the study. ? Proportion of women that will require oxytocin augmentation in achieving vaginal delivery in both groups of the study. ? Incidence of maternal side effect (tachystole, uterine rupture, shivering, diarrhea) in both groups of the study. ? Incidence of adverse perinatal outcomes (fetal distress, poor apgar score, NICU admission) in both groups of the study.	—

Measure

Time frame

? The induction-delivery interval in both groups of the study. ? Proportion of women that will require oxytocin augmentation in achieving vaginal delivery in both groups of the study. ? Incidence of maternal side effect (tachystole, uterine rupture, shivering, diarrhea) in both groups of the study. ? Incidence of adverse perinatal outcomes (fetal distress, poor apgar score, NICU admission) in both groups of the study.

—

Countries

Nigeria

Contacts

Public ContactRabiat Aliyu

Secondary researcher

rabaahmb@ymail.com+2348037016884

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026